Cancer Research UK
Clinical Trials Unit Glasgow

Trials (Closed)

To download the Trial Protocol or Trial Publication, please click on the relevant link.

Tumour Site Trial Acronym Trial Description Protocol Publication
CIRCCA A Randomised Double Blind Phase II trial of carboplatin-paclitaxel plus cediranib versus carboplatin-paclitaxel plus placebo in metastatic/recurrent cervical cancer. CIRCCa Protocol
LMS study A Phase III Randomised Trial of Gemcitabine plus Docetaxel followed by Doxorubicin versus Observation for Uterus Limited, High Grade Uterine Leiomyosarcoma.
LOGS A randomised phase II/III study to assess the efficacy of trametinib (GSK 1120212) in patients with recurrent or progressive low-grade serous ovarian cancer of peritoneal cancer (GOG-0281).
OPSROC A prospective randomized Phase III Trial of Carboplatin / gemcitabine / bevacizumab vs pegylated liposomal doxorubicin / gemcitabine / bevacizumab in patients with platinum-sensitive recurrent ovarian cancer.
CHOICES A randomised Phase II trial of Imatinib (IM) versus Hydroxychloroquine (HCQ) and IM for patients with Chronic Myeloid Leukaemia (CML) in Major Cytogenetic Response (MCyR) with residual disease detectable by quantitative polymerase chain reaction (Q-PCR).
CUP ONE A multi-centre phase II trial to assess the efficacy of epirubicin, cisplatin and capecitabine in carcinomas of unknown primary (CUP): incorporating the prospective validation of molecular classifiers in diagnosis and classification and exploratory metabonomics.
CAVA A randomised controlled trial with associated qualitative research of venous access devices for the delivery of long-term chemotherapy.
Carmena A Randomised phase III trial to evaluate the benefit of nephrectomy followed by antiangiogenic treatment versus antiangiogenic treatment alone in patients with metastatic at diagnosis kidney cancer. Carmena publication
MADCAP A phase I/randomised phase II trial of abiraterone acetate or enzalutamide with or without idasanutlin (RO5503781) in patients with metastatic Castrate Resistant Prostate Cancer (mCRPC) who have not previously received docetaxel.
SPECTRE Combined Suppression Of Cholesterol Bioavailability And Androgen Deprivation Therapy To Treat Castration Resistant Prostate Cancer.